Relevant bibliographies by topics / Tumor Residual

Academic literature on the topic 'Tumor Residual'

Author: Grafiati
Published: 9 March 2023
Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Tumor Residual.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Tumor Residual"

1

Panni, Roheena Z., Ivan Gonzalez, Christopher P. Hartley, Gregory A. Williams, Jingxia Liu, William G. Hawkins, and Deyali Chatterjee. "Residual Tumor Index." American Journal of Surgical Pathology 42, no. 11 (November 2018): 1480–87. http://dx.doi.org/10.1097/pas.0000000000001144.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wittekind, Christian, and Paul Hermanek. "Residual Tumor Classification." Advances in Anatomic Pathology 2, no. 4 (July 1995): 277–79. http://dx.doi.org/10.1097/00125480-199507000-00055.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kishida, Takeshi. "Postchemotherapy residual tumor." Annals of Oncology 28 (October 2017): ix52. http://dx.doi.org/10.1093/annonc/mdx627.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kasbekar, Anand, Guleed Adan, Alaina Beacall, Ahmed Youssef, Catherine Gilkes, and Tristram Lesser. "Growth Patterns of Residual Tumor in Preoperatively Growing Vestibular Schwannomas." Journal of Neurological Surgery Part B: Skull Base 79, no. 04 (November 8, 2017): 319–24. http://dx.doi.org/10.1055/s-0037-1607421.

Full text
Abstract:
Objectives To analyze growth of residual vestibular schwannoma (VS) following incomplete tumor resection and determine the influence of residual location and size. Design Retrospective case note and scan review. Setting Tertiary skull base unit. Participants Patients with residual tumor following primary surgery for medium and large unilateral growing vestibular schwanomas between 2006 and 2009. Main Outcome Measures Location of residual VS and post-operative growth, comparing those with more (>5%) or less than 5% of tumor residual (<5%). Results Fifty-two patients had visible residual tumor left behind at surgery. Twenty had < 5% and 32 had > 5% residual. The residual growth rates were 38% overall, 20% in < 5%, and 50% in > 5% residuals. There was no significant difference in growth rates at different residual locations. Median follow-up was 6.4 years. Conclusions There is a greater risk of regrowth of residuals > 5%. All positions of residual tumor can regrow, and the preoperative tumor size plays a role in this. Further data is needed to confirm if residual tumor in the fundus is less likely to grow.
APA, Harvard, Vancouver, ISO, and other styles
5

Lusch, A., and P. Albers. "Residual tumor resection (RTR)." World Journal of Urology 35, no. 8 (December 21, 2016): 1185–90. http://dx.doi.org/10.1007/s00345-016-1984-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Xu, Xiaohong, Liangping Luo, Jiexin Chen, Jiexin Wang, Honglian Zhou, Mingyi Li, Zhanqiang Jin, et al. "Acoustic Radiation Force Impulse Elastography for Efficacy Evaluation after Hepatocellular Carcinoma Radiofrequency Ablation: A Comparative Study with Contrast-Enhanced Ultrasound." BioMed Research International 2014 (2014): 1–7. http://dx.doi.org/10.1155/2014/901642.

Full text
Abstract:
Aim. To explore acoustic radiation force impulse (ARFI) elastography in assessing residual tumors of hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA).Materials and Methods. There were 83 HCC lesions among 72 patients. All patients were examined with ARFI, contrast enhanced ultrasound (CEUS), and CT or MRI. Tumor brightness on virtual touch tissue imaging (VTI) and shear wave velocity (SWV) were assessed before and approximately one month after RFA.Results. There were 14 residual tumors after RFA. VTI showed that all the tumors were darker after RFA. VTI was not able to distinguish the ablated lesions and the residual tumors. 13 residual tumor lesions were detected by CEUS. All completely ablated nodules had SWV demonstration of x.xx., while with those residual nodules, 6 tumors had x.xx measurement and 8 tumors had measurable SWV. nine lesions with residual tumors occurred in cirrhosis subjects and 5 lesions with residual tumors occurred in fibrosis subjects; there was no residual tumor in the normal liver subjects.Conclusion. VTI technique cannot demonstrate residual tumor post RFA. While SWV measurement of less than x.xx is likely associated with residual tumors, measurement of less than x.xx cannot exclude residual tumors. Liver cirrhosis is associated with decreased chance of a complete ablation.
APA, Harvard, Vancouver, ISO, and other styles
7

Yi, Huiming, Baohuan Cai, Xi Ai, Kaiyan Li, Pengfei Song, and Wei Zhang. "Early Identification of Residual Tumors following Microwave Ablation Using Contrast-Enhanced Ultrasonography in a Rabbit VX2 Liver Cancer Model." BioMed Research International 2020 (September 27, 2020): 1–9. http://dx.doi.org/10.1155/2020/2462058.

Full text
Abstract:
Objective. It is difficult to evaluate the ablation effect immediately after thermal ablation of liver cancer by clinical imaging methods, due to the immediate formation of an annular inflammatory reaction band (IRB). This study is aimed at exploring the early identification indicators of the IRB and residual tumor postmicrowave ablation (MVA) using contrast-enhanced ultrasonography (CEUS). Methods. MVA was used to inactivate part of the tumor nodules in rabbit VX2 liver cancer models, leading to the coexistence of the IRB with residual tumors. Quantitative analysis of the perfusion parameters of the tumor and ablation zone was performed using CEUS, followed by liver biopsy and VEGFR-2 immunohistochemical staining. Results. All rabbits successfully tolerated VX2 tumor inoculation and MVA operation. No statistically significant difference existed between the IRB vs. residual tumors, the IRB vs. junctional areas, and residual tumors postablation vs. VX2 tumors before ablation in regional blood volume, blood velocity, and blood flow estimated by parameters A, k, and A∗k of CEUS quantitative analysis. There was a statistically significant difference between the IRB and normal liver parenchyma in regional blood velocity and blood flow (p=0.005 and p=0.023, respectively). Normal liver parenchyma showed nonspecific VEGFR-2 staining, while VX2 tumor before ablation and residual tumor after ablation both showed positive VEGFR-2 staining; the necrosis zone showed negative staining by VEGFR-2 immunohistochemical staining. Conclusion. MVA had no significant effect on the residual tumor hemodynamics. The blood flow in the IRB increased significantly as compared to normal liver parenchyma, resembling tumor hemodynamic patterns. CEUS can detect residual tumors immediately postablation only when they protrude from the annular-shaped IRB. In addition, VEGFR-2 targeted CEUS may have a great potential for detecting residual tumor after thermal ablation of hepatocellular carcinoma.
APA, Harvard, Vancouver, ISO, and other styles
8

Widhalm, Georg, Stefan Wolfsberger, Matthias Preusser, Ingeborg Fischer, Adelheid Woehrer, Joerg Wunderer, Johannes A. Hainfellner, and Engelbert Knosp. "Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression." Journal of Neurosurgery 111, no. 3 (September 2009): 563–71. http://dx.doi.org/10.3171/2008.4.17517.

Full text
Abstract:
Object In residual nonfunctioning pituitary adenomas, reliable prognostic parameters indicating probability of tumor progression are needed. The Ki 67 expression/MIB-1 labeling index (LI) is considered to be a promising candidate factor. The aim in the present study was to analyze the clinical usefulness of MIB-1 LI for prognosis of tumor progression. Methods The authors studied a cohort of 92 patients with nonfunctioning pituitary adenomas. Based on sequential postoperative MR images, patients were classified as tumor free (51 patients) or as harboring residual tumor (41 individuals). The residual tumor group was further subdivided in groups with stable residual tumors (14 patients) or progressive residual tumors (27 patients). The MIB-1 LI was assessed in tumor specimens obtained in all patients, and statistical comparisons of MIB-1 LI of the various subgroups were performed. Results . The authors found no significant difference of MIB-1 LI in the residual tumor group compared with the tumor-free group. However, MIB-1 LI was significantly higher in the progressive residual tumor group, compared with the stable residual tumor group. Additionally, the time period to second surgery was significantly shorter in residual adenomas showing an MIB-1 LI > 3%. Conclusions The data indicate that MIB-1 LI in nonfunctioning pituitary adenomas is a clinically useful prognostic parameter indicating probability of progression of postoperative tumor remnants. The MIB-1 LI may be helpful in decisions of postoperative disease management (for example, frequency of radiographic intervals, planning for reoperation, radiotherapy, and/or radiosurgery).
APA, Harvard, Vancouver, ISO, and other styles
9

De Santis, Maria, Alexander Becherer, Carsten Bokemeyer, Franz Stoiber, Karin Oechsle, Franz Sellner, Alois Lang, et al. "2-18fluoro-deoxy-D-glucose Positron Emission Tomography Is a Reliable Predictor for Viable Tumor in Postchemotherapy Seminoma: An Update of the Prospective Multicentric SEMPET Trial." Journal of Clinical Oncology 22, no. 6 (March 15, 2004): 1034–39. http://dx.doi.org/10.1200/jco.2004.07.188.

Full text
Abstract:
Purpose To define the clinical value of 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG PET) as a predictor for viable residual tumor in postchemotherapy seminoma residuals in a prospective multicentric trial. Patients and Methods FDG PET studies in patients with metastatic pure seminoma who had radiographically defined postchemotherapy residual masses were correlated with either the histology of the resected lesion or the clinical outcome documented by computer tomography (CT), tumor markers, and/or physical examination during follow-up. The size of the residual lesions on CT, either > 3 cm or ≤ 3 cm, was correlated with the presence or absence of viable residual tumor. Results Fifty-six FDG PET scans of 51 patients were assessable. All 19 cases with residual lesions > 3 cm and 35 (95%) of 37 with residual lesions ≤ 3 cm were correctly predicted by FDG PET. The specificity, sensitivity, positive predictive value, and negative predictive value of FDG PET were 100% (95% CI, 92% to 100%), 80% (95% CI, 44% to 95%), 100%, and 96%, respectively, versus 74% (95% CI, 58% to 85%), 70% (95% CI, 34% to 90%), 37%, and 92%, respectively, for CT discrimination of the residual tumor by size (> 3 cm/≤ 3 cm). Conclusion This investigation confirms that FDG PET is the best predictor of viable residual tumor in postchemotherapy seminoma residuals and should be used as a standard tool for clinical decision making in this patient group.
APA, Harvard, Vancouver, ISO, and other styles
10

Morita, Yoshihiro, Macall Leslie, Hiroyasu Kameyama, Ganesh L. R. Lokesh, Norihisa Ichimura, Rachel Davis, Natalie Hills, et al. "Functional Blockade of E-Selectin in Tumor-Associated Vessels Enhances Anti-Tumor Effect of Doxorubicin in Breast Cancer." Cancers 12, no. 3 (March 19, 2020): 725. http://dx.doi.org/10.3390/cancers12030725.

Full text
Abstract:
Chemotherapy is a mainstay of treatment for solid tumors. However, little is known about how therapy-induced immune cell infiltration may affect therapy response. We found substantial CD45+ immune cell density adjacent to E-selectin expressing inflamed vessels in doxorubicin (DOX)-treated residual human breast tumors. While CD45 level was significantly elevated in DOX-treated wildtype mice, it remained unchanged in DOX-treated tumors from E-selectin null mice. Similarly, intravenous administration of anti-E-selectin aptamer (ESTA) resulted in a significant reduction in CD45+ immune cell density in DOX-treated residual tumors, which coincided with a delay in tumor growth and lung metastasis in MMTV-pyMT mice. Additionally, both tumor infiltrating T-lymphocytes and tumor associated-macrophages were skewed towards TH2 in DOX-treated residual breast tumors; however, ESTA suppressed these changes. This study suggests that DOX treatment instigates de novo intratumoral infiltration of immune cells through E-selectin, and functional blockade of E-selectin may reduce residual tumor burden as well as metastasis through suppression of TH2 shift.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Tumor Residual"

1

Takeda, Kazuna. "MRI evaluation of residual tumor size after neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy." Kyoto University, 2012. http://hdl.handle.net/2433/157449.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Oliveira, Marcelo de Lima. "Ultrassonografia durante cirurgia para metástase cerebral: influência no índice de Karnofsky e volume do tumor residual." Universidade de São Paulo, 2016. http://www.teses.usp.br/teses/disponiveis/5/5138/tde-09082016-151729/.

Full text
Abstract:
Introdução: Os principais objetivos do tratamento das metástases cerebrais (MC) são no auxílio do controle da doença no encéfalo e a melhora da qualidade de vida dos pacientes. A cirurgia convencional tem um importante papel no tratamento das MCs e os métodos de monitoração intraoperatória podem auxiliar na obtenção de resultados cirúrgicos melhores. Objetivos: Avaliar a influência da ultrassonografia encefálica durante cirurgia para ressecção de MC no índice de Karnofsky e no grau de ressecção do tumor. Métodos: Neste estudo prospectivo controlado e não randomizado, doentes com indicação de tratamento cirúrgico de MCs foram incluídos. A ultrassonografia intraoperatória (USIO) foi realizada por um neurossonologista. O índice de Karnofsky foi avaliado por equipe multidisciplinar de oncologia; o grau de dificuldade para ressecção cirúrgica do tumor foi avaliado pelo cirurgião e o volume tumoral foi avaliado pelo neurorradiologista por meio da RM realizada no pré e pós-operatório. Resultados: Dos 78 doentes, 40 homens e 38 mulheres com idade média de 53 anos, 35 foram submetidos a tratamento cirúrgico com auxílio da USIO. Não houve diferença estatística no KPS e volume tumoral pré-operatório entre os grupos. O KPS pós-operatório no grupo da USIO foi de 80 e no grupo-controle de 70 (p=0,045). Considerando-se a melhora do KPS no pós-operatório, a quantidade de doentes tiveram melhora do KPS foi superior no grupo da USIO (p=0,036) destacando-se os seguintes subgrupos: tumores com grau de dificuldade de ressecção < 4 (p=0,037), tumores nas áreas eloquentes (p=0,043), tumores não relacionados aos grandes vasos e nervos (p=0,007), e lesões únicas no leito cirúrgico (p=0,038). O tumor residual na RM pós-operatória foi menor no grupo da USIO: 9,5% no grupo da USIO e 30,8% no grupo-controle; 1,6 mm3 no grupo da USIO e 9 mm3 do grupo-controle; p=0,05. Considerando-se doentes com KPS >= 70, o número de doentes com volume de tumor residual inferior a 10% em relação ao volume pré-operatório foi superior no grupo da USIO (p=0,032 e OR de 3,8). Conclusão: Os achados deste estudo sugerem que a USIO encefálica pode influenciar na melhora do índice de Karnofsky e na redução do volume de tumor residual
Object: The goals of treating a cerebral metastasis (CM) are to achieve local control of the disease and to improve patient quality of life. The aim of this study was to analyse the effect of using conventional surgery supported by intra-operative ultrasound (IOUS) to approach a CM. To perform this analysis, we determined Karnofsky post-operative scores (KPS) and tumour resection grades. Methods: Patients with CM who were eligible to undergo a surgical approach were included in this study. Surgical treatment was either supported or not supported by IOUS. A neural oncology team determined the pre- and post-operative KPS. A radiologist examined the tumour volume using pre- and post-operative magnetic resonance imaging. Before the surgery, the surgeon determined whether it was possible to perform a total CM resection. Results: A total of 78 patients with CM diagnosis were treated using a surgical approach (35 with and 43 without IOUS). The post-operative median KPS was higher in the IOUS group (80 versus 70, p=0.045). Within the IOUS group, KPS evolution was superior (p=0.036), especially in the following CM subgroups: a difficulty of tumour resection ranking score<4 (p=0.037), the tumour was in an eloquent area (p=0.043), the tumour was not associated with vessels or nerves (p=0.007), and solitary lesions (p=0.038). The volume of residual tumours was lower in the IOUS group (9.5% and 1.6 mm3 versus 30.8% and 9 mm3, p=0.05). In patients with a KPS >= 70, the residual tumour volume was categorized as < 10% or >= 10%, and 62% of patients had < 10% residual tumours (76% in the IOUS group and 45% in the non-IOUS group; p=0.032 and OR=3.8). Conclusion: This study suggests that IOUS can play a role in improving post-operative KPS and in decreasing residual tumours in CM surgeries
APA, Harvard, Vancouver, ISO, and other styles
3

Costa-Gurgel, Maria Salete 1956. "Aspectos histologicos relacionados com a persistencia de tumor residual apos conização em pacientes com carcinoma microinvasivo do colo uterino." [s.n.], 1994. http://repositorio.unicamp.br/jspui/handle/REPOSIP/310012.

Full text
Abstract:
Orientador: Aloisio José Bedone
Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas
Made available in DSpace on 2018-07-19T18:28:24Z (GMT). No. of bitstreams: 1 Costa-Gurgel_MariaSalete_M.pdf: 1948436 bytes, checksum: 9652cc74f1c4e8abd0a8359398a304a0 (MD5) Previous issue date: 1994
Resumo: O tratamento do carcinoma microinvasivo do colo uterino é bastante controverso, sendo abordado diferentemente nos diversos Serviços. A histerectomia, acompanhada ou não de procedimentos mais radicais, é realizada na quase totalidade dos casos. Mais recentemente, tem-se observado uma tendência à adoção de condutas conservadoras, como a conização nos casos de invasão inicial, desde que se tenha segurança da retirada total da neoplasia. Através da revisão anatomopatológica dos 163 casos tratados no Ambulatório de Oncologia Ginecológica do Departamento de Tocoginecologia da FCM/UNICAMP, no período de 1967 a 1994, que foram submetidos à histerectomia simples ou radical após conização, procuramos estabelecer os fatores de risco para a persistência de tumor residual após esta cirurgia. Não houve influência das dimensões da microinvasão medidas pela profundidade e extensão horizontal da lesão, assim como do seu aspecto focal ou extenso e da presença de invasão vascular do estroma na ocorrência de neoplasia residual. Na análise inicial, o comprometimento das margens cirúrgicas da conização e a presença de sinais histológicos compatíveis com infecção pelo HPV demonstraram estar associados a um aumento significativo de neoplasia residual após conização uterina nos casos de carcinoma microinvasivo do colo uterino. No entanto, ao final do estudo, observou-se que houve interação entre os sinais de HPV e o comprometimento das margens cirúrgicas da conização na presença de tumor residual.
Abstract: The treatment of microinvasive carcinoma of the uterine cervix is controversial, with different approaches by different services. Hysterectomy in performed in almost all cases, associated or not with more radical procedures. Nowadays, there is a trend in adopting conservative conducts, such as conization in patients with early invasion, as long as there can be assured that the whole lesion was removed. Through histological review of 163 cases treated at the Gynecological Oncology Out patient Clinic if the Department of Gynecology and Obstetrics of the University of Campinas, from 1967 to 1994, ali of them undergone simple or radical hysterectomy after conization, it was tried to stablish the risk factors for persistency of residual tumor after conization. The microinvasion size measured by the depth and length of the lesion, its focal or extensive pattern and the presence of stromal vascular space involvement did not influence the occurrence of residual tumor. Initially the surgical margins involvement in conization and the presence of HPV histological signs were associated with on increased incidence of residual tumor after this procedure. Nonetheless, the statistical analysis showed that there was interaction between HPV histological signs and surgical margins involvement on residual tumor.
Mestrado
Mestre em Tocoginecologia
APA, Harvard, Vancouver, ISO, and other styles
4

Marighetti, P. "RESIDUAL DORMANT CANCER STEM CELL FOCI ARE RESPONSIBLE FOR TUMOR RELAPSE AFTER ANGIOGENIC METRONOMIC THERAPY IN HEPATOCELLULAR CARCINOMA XENOGRAFTS." Doctoral thesis, Università degli Studi di Milano, 2012. http://hdl.handle.net/2434/169919.

Full text
Abstract:
Hepatocellular carcinoma (HCC) is the fifth most common solid tumor and the third leading cause of cancer-related death. Current available chemotherapeutic options are not curative due in part to their resistance to conventional therapies. We have generated orthotopic HCC mouse models in immunodeficient NOD/SCID/IL2rγ null mice by injection of AFP- and/or luciferase-expressing HCC cell lines and primary cells from patients, where tumor growth and spread can be accurately monitored in a non-invasive way. Low dose metronomic administration of cyclophosphamide (LDM-CTX) causes in this model complete regression of the tumor mass with a significant increase in survival (p<0.0001), and reduction in aberrant angiogenesis, IL-6 and TNFα (but not VEGF) levels, hyperproliferation, and alteration of normal liver parenchyma, compared to untreated animals. However, the presence of residual circulating hAFP levels suggested that some tumor cells were still present in livers of treated mice. Immunohistochemistry revealed that those cells had a hAFP+/CD13+/PCNA- phenotype, suggesting that they were dormant cancer stem cells (CSC). Indeed, off-therapy mice developed rapidly tumor growth, which was still sensitive to LDM-CTX therapy. The capacity of developing hepatoshperes in vitro was drastically reduced upon LDM-CTX treatment, which resulted in selection of CD13+ cells, showing that these cells are particularly resistant to therapy. Co-treatment of the CD13-targeting drug bestatin with LDM-CTX resulted in a dramatic reduction in tumor burden. Therefore, our results demonstrate the therapeutic efficacy of administering LDM-CTX and targeting the residual CD13+ CSC-like population in these novel orthotopic HCC models, and strongly suggests that this therapy could be implemented in clinical trials.
APA, Harvard, Vancouver, ISO, and other styles
5

Vu-Han, Tu-Lan [Verfasser], and Reinhard [Akademischer Betreuer] Schneppenheim. "Identifying Molecular Markers for the Sensitive Detection of Residual Atypical Teratoid Rhaboid-Tumor Cells / Tu-Lan Vu-Han. Betreuer: Reinhard Schneppenheim." Hamburg : Staats- und Universitätsbibliothek Hamburg, 2016. http://d-nb.info/1082347604/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Vu-Han, Tu-Lan Verfasser], and Reinhard [Akademischer Betreuer] [Schneppenheim. "Identifying Molecular Markers for the Sensitive Detection of Residual Atypical Teratoid Rhaboid-Tumor Cells / Tu-Lan Vu-Han. Betreuer: Reinhard Schneppenheim." Hamburg : Staats- und Universitätsbibliothek Hamburg, 2016. http://nbn-resolving.de/urn:nbn:de:gbv:18-77221.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Morales, Murillo Serafín. "Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0cm.) tras Quimioterapia neoadyuvante." Doctoral thesis, Universitat de Lleida, 2015. http://hdl.handle.net/10803/401677.

Full text
Abstract:
La identificació de marcadors moleculars en el tumor residual després de quimioteràpia neoadjuvant ( QTN ) en Càncer de Mama permet una millor caracterització pronostica . S'han seleccionat un total de 256 pacients amb QTN entre 1996 i 2011 , amb tumor residual ( > 1 cm ) . S'ha realitzat una matriu matricial de teixits i estudi inmunohistoquimic de l'expressió de 29 marcadors moleculars . L'anàlisi s'ha realitzat sobre l'aparició de metàstasi i la supervivència lliure de progressió a distància . El model multivariant ( mètode stepwise ) obté una signatura molecular amb sis marcadors de mal pronòstic : ER [ = 0 ] , cit - P65 [ < 85 ] , cit - HER4 [ > 75 ] , cit - PTEN [ = 0 ] , BCL2 [ < 78 ] i Ki67 [ > 20 ] . Una anàlisi en funció de l'expressió de receptors de estrògens identifica marcadors associats a mal pronòstic en RE -negatiu [ = 0 ] : ]: HER4-cit [>70] (p 0.01), P65-nuc [>37] (p 0.01), BP1 [>100] (p 0.001) p65-cit [<85] (p 0.04) E-Cad-cit [>80] (p 0.04) y GATA 3 [<145] (p 0,05), mentre que per RE - positiu [ > 0 ] : Ciclina D1-nuc [>145] (p 0.02) Ki67 [>24] (p 0.02) Survivina-nuc [<90] (p 0.02) i pAKT-cit [>145] (p 0.03)
La identificación de marcadores moleculares en el tumor residual tras quimioterapia neoadyuvante (QTN) en Cáncer de Mama permite una mejor caracterización pronostica. Se han seleccionado un total de 256 pacientes con QTN entre 1996 y 2011, con tumor residual (> 1 cm). Se ha realizado un array matricial de tejidos y estudio IHQ de la expresión de 29 marcadores moleculares. El análisis se ha realizado sobre la aparición de metástasis y la supervivencia libre de progresión a distancia. El modelo multivariante (método stepwise) obtiene una firma molecular con seis marcadores de mal pronóstico: ER [= 0], cit-P65 [<85], cit-HER4 [> 75], cit-PTEN [= 0], BCL2 [<78] y KI67 [> 20]. Un análisis en función de la expresión de RE identifica marcadores asociados a mal pronostico en RE-negativo [=0]: HER4-cit [>70] (p 0.01), P65-nuc [>37] (p 0.01), BP1 [>100] (p 0.001) p65-cit [<85] (p 0.04) E-Cad-cit [>80] (p 0.04) y GATA 3 [<145] (p 0,05) , mientras que para RE-positivo [>0]: Ciclina D1-nuc [>145] (p 0.02) Ki67 [>24] (p 0.02) Survivina-nuc [<90] (p 0.02) y pAKT-cit [>145] (p 0.03) .
Identification of molecular markers in the residual tumor after neoadjuvant chemotherapy ( QTN ) in breast cancer allows better prognostic characterization . A total of a total of 256 patients between 1996 and 2011 QTN with residual tumor ( > 1 cm) have been selected . A tissue array and inmunohistochemistry study of expression of 29 molecular markers has been performed. The analysis was conducted on the occurrence of metastasis and progression-free survival distance. The multivariate model ( stepwise method ) obtained a molecular signature of six prognostic markers : ER [= 0] , cit - P65 [ < 85 ] , cit - HER4 [ > 75 ] , cit - PTEN [= 0] , BCL2 [ < 78 ] and Ki67 [ > 20 ] . An analysis based on the expression of estrogen receptor identifies markers associated with poor prognosis in ER - negative [= 0 ]: HER4-cit [>70] (p 0.01), P65-nuc [>37] (p 0.01), BP1 [>100] (p 0.001) p65-cit [<85] (p 0.04) E-Cad-cit [>80] (p 0.04) y GATA 3 [<145] (p 0,05) , whereas ER - positive [ > 0 ] : Ciclina D1-nuc [>145] (p 0.02) Ki67 [>24] (p 0.02) Survivina-nuc [<90] (p 0.02) y pAKT-cit [>145] (p 0.03).
APA, Harvard, Vancouver, ISO, and other styles
8

PEIRETTI, MICHELE. "Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. single institution experience." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2010. http://hdl.handle.net/10281/8049.

Full text
Abstract:
Objective. The objective of the present study was to determinate the impact of maximal cytoreductive surgery on progression free survival, overall survival rates and morbidity, in patients with advanced epithelial ovarian or fallopian tube cancer (stage IIIC-IV) treated in a referral cancer center. Methods. After obtaining Institutional Review Board approval, we reviewed all medical records of patients with stage IIIC–IV epithelial ovarian cancer who were managed at our institution between January 2001 and December 2008. Individual records were reviewed and the following information collected: age at surgery, date of surgery, American Society of Anestesiology (ASA) class, primary site of disease, presence of peritoneal carcinomatosis, histologic type and tumor grade, pre-operative serum CA-125 level, location and size of the largest tumor mass, the initial ascites volume (if present), all surgical procedures performed, size of residual disease after surgery. The Kaplan–Meier method was used to estimate survival curves. Cox proportional hazards regression was performed to identify independent prognostic variables for overall survival by univariate and multivariate analysis. Results. A total of 269 patients with advanced epithelial ovarian cancer were referred to our institution between January 2001 and December 2008, and of them 240 consecutive patients met inclusion criteria for the study. The median age was 58 years (range 22 to 77 years). After a median follow up of 29.8 months, the overall median survival (OS) and progression free survival (PFS) were 61.1 and 20.4 months respectively. On univariate analysis, factors significantly associated with decreased survival included: age grater than median (>60 years), presence of ascites >1000 cc, diffuse peritoneal carcinomatosis, omentum as anatomical location of the largest tumor mass, positive lymph-nodes and diameter of residual disease. On multivariate analysis confirmed the independent association of age grater than 60 years and residual disease > 5 mm with worse survival. Conclusion. Our study seems to demonstrate that a more extensive surgical approach is associated with improved survival in patients with stages IIIC-IV epithelial ovarian cancer. Age grater than 60 years and residual tumor grater than 5 mm were independently associated with a worse prognosis.
APA, Harvard, Vancouver, ISO, and other styles
9

Milano, Jeronimo Buzetti. "Estudo das alterações em exames de ressonância magnética de pacientes em pós-operatório imediato de ressecção de tumores hipofisários por via transesfenoidal." Universidade de São Paulo, 2010. http://www.teses.usp.br/teses/disponiveis/5/5138/tde-22062010-125138/.

Full text
Abstract:
Exames pós-operatórios de cirurgias intracranianas são difíceis de serem interpretados por apresentarem alterações morfológicas que simulam situações patológicas, como edema e tumores residuais. Com o advento de métodos de ressonância intraoperatória essa interpretação ganhou maior importância, pelo risco de re-intervenções desnecessárias. O presente estudo objetivou estabelecer as características de exames pós-operatórios normais após remoção de tumores hipofisários pela via transesfenoidal endonasal, bem como estabelecer parâmetros de remoção tumoral radical para otimização de exames intraoperatórios. Foram estudados 40 pacientes (22 microadenomas e 18 macroadenomas) operados consecutivamente no Instituto de Neurologia de Curitiba, portadores de adenomas hipofisários, pela via transesfenoidal endonasal, e que realizaram exame de ressonância magnética (RM) dinâmica no pré-operatório, pós-operatório imediato (primeiras 24horas após o término da cirurgia) e após três meses.Foram utilizadas sequências ponderadas em T1, com cortes coronais de 3mm antes da injeção de contraste (gadopentetato dimeglumina Gd-DTPA) e a cada 90 segundos após a injeção rápida do mesmo. Os achados de RM dinâmica no pós-operatório imediato foram analisados quanto ao deslocamento da haste hipofisária, presença de material hiperintenso intrasselar, deslocamento do diafragma selar superiormente (caracterizado pela classificação de Hardy para extensões suprasselares) e quanto ao padrão de captação de contraste na RM dinâmica. Os padrões de captação foram classificados como: 1. ausência de captação de contraste, 2. realce anelar periférico, 3. captação nodular e 4. padrão misto (periférico e nodular coexistentes). No exame pós-operatório tardio, ênfase foi dada na presença de tumor residual, confirmada por alteração hormonal ou re-operação com histopatologia.As alterações de imagem foram descritas em termos de prevalência de ocorrência (porcentagem), e correlacionadas com a existência ou não de tumores residuais no pós-operatório tardio. Observouse deslocamento da haste hipofisária em 95% dos casos (90,9% dos microadenomas e 100% dos macroadenomas). Material hiperintenso intrasselar ocorreu em 77,3% dos microadenomas e 100% dos macroadenomas (87,5% do total). O deslocamento cranial do diafragma selar manteve inalterado em 16 dos 18 casos (88,9%). A padrão de captação de contraste foi o tipo 1 em 90,9% dos microadenomas, com apenas 2 casos (9,1%) com captação periférica (tipo 2) neste grupo. Nos macroadenomas, 66,7% foram tipo 1, 5,5% tipo 2, 16,7% tipo 3 e 11,1% tipo 4. No pós-operatório tardio, o material hiperintenso desapareceu em todos os casos, com a haste hipofisária retornando à posição habitual em 81,8% dos casos. Cinco pacientes apresentavam tumores residuais, confirmados por alteração hormonal em dois casos e reoperação em três. Destes, três apresentavam padrão tipo 4 de captação de contraste, e dois do tipo 3. A correlação entre o padrão de captação nodular, isolado ou combinado, com a presença de tumor residual foi de 100%. Todos os outros achados devem ser considerados normais no pós-operatório
Imaging after intracranial surgeries is difficult to evaluate because usual changes often simulates pathological findings, such as edema and residual tumors. Emerging technologies of intraoperative magnetic resonances lead to a greater interest on understanding usual findings, in order to avoid unnecessary revisions. The objective of this study was to establish normal postoperative findings on dynamic magnetic resonance imaging (dMRI) after resection of pituitary tumors through endonasal transsphenoidal approach, as well as determine parameters of radical resection, thus optimizing intraoperative images. Forty patients (22 microadenomas and 18 macroadenomas) operated on the Instituto de Neurologia de Curitiba for pituitary adenomas through endonasal transsphenoidal approach were evaluated by dMNRI before, within the first 24 hours and after three months of the surgery. T1-weighted images on coronal plane, 3mm slices were performed before and on every 90 seconds after rapid injection of the paramagnetic contrast (gadopentetate dimeglumine GdDTPA). Findings analyzed at early postoperative dMRI were: lateral displacement of the pituitary stalk, hyperintense intraselar material, position of the diafragma selae (as classified by Hardy, for supraselar extensions) and the pattern of contrast enhancement: 1. no enhancement, 2. peripheral ring, 3. nodular enhancement and 4. combined peripheral and nodular. At late postoperative MRI, the regression of early findings was noted, as well as the presence of a residual tumor. This late was confirmed by hormonal essay or hystopathological examination (reoperation). Findings were first described as prevalence (%), and then related to the presence or not of a residual tumor at late postoperative MRI. Displacement of the pituitary stalk was noted in 95% of cases (90,9% in microadenomas, and 100% in macroadenomas). Hyperintense intraselar material was found in 77,3% of microadenomas and 100% of macroadenomas (87,5% of all cases). Supraselar extension remained unaltered in 16 of 18 cases (88,9%). Pattern of enhancement was type 1 in 90,9% of the microadenomas, with only two cases (9,1%) with peripheral ring. Of the macroadenomas, 66,7% had type 1 pattern, 5,5% type 2, 16,7% type 3 and 11,1% type 4. At late postoperative MRI, the hyperintense material disappeared in all cases, with the pituitary stalk returning to the midline in 81,8% of the cases. Five patients had residual tumors, confirmed by hormonal essay in two cases, and re-operated (with hystopathological confirmation) in three. Of these, three had type 4 pattern of enhancement, and two had type 3. When the nodular enhancement, alone or combined, was correlated with the presence of a residual tumor, the association was of 100%. The other findings described should be considered normal findings
APA, Harvard, Vancouver, ISO, and other styles
10

Rick, Oliver. "Therapieoptimierungsverfahren bei Patienten mit rezidivierten oder progredienten Keimzelltumoren." Doctoral thesis, Humboldt-Universität zu Berlin, Medizinische Fakultät - Universitätsklinikum Charité, 2004. http://dx.doi.org/10.18452/13921.

Full text
Abstract:
Patienten mit metastasierten Keimzelltumoren, die einen Progress oder ein Rezidiv ihrer Erkrankung nach einer cisplatinhaltigen Vortherapie erleiden, haben eine schlechte Prognose. Unter Verwendung einer erneuten konventionellen Chemotherapie können maximal 15-30% dieser Patienten geheilt werden, so dass die Mehrzahl der Patienten an ihrer Erkrankung verstirbt. Aus diesem Grund ist die Optimierung der therapeutischen Möglichkeiten ein wesentliches Ziel. Unsere Daten zeigen, dass die Hochdosischemotherapie (HDCT) eine wesentliche therapeutische Verbesserung darstellt und mittels dieser Therapie mit einem ereignisfreien Überleben von 30-60% zu rechnen ist. Eine "matched-pair" Analyse konnte im Hinblick auf das ereignisefreie und das Gesamtüberleben einen Vorteil von mehr als 10% zu Gunsten der HDCT feststellen. Darüber hinaus hat die zunehmende Erfahrung und die Verwendung von peripheren Blutstammzellen und hämatopoetischen Wachstumsfaktoren, den Einsatz der HDCT deutlich sicherer gemacht. Aus den genannten Gründen sollte alle Patienten mit Rezidiv oder Progress eines Keimzelltumors der HDCT zugeführt werden. Die operative Entfernung von residuellen Tumormanifestationen (RTR) nach primärere Chemotherapie ist heute Standard bei Patienten mit metastasierten Keimzelltumoren. Zwar findet sich in der histologischen Aufarbeitung bei den meisten Patienten ausschließlich nekrotisches Gewebe, doch werden bei einem Teil der Patienten auch Anteile von reifem Teratom und vitalen differenzierten und undifferenzierten Karzinomen gefunden. Während die Resektion von Nekrose keinen therapeutischen Benefit für den Patienten darstellt, ist die komplette Entfernung von reifem Teratom oder Zellen eines Karzinoms für die Prognose entscheidend. In Bezug auf die HDCT konnten bisher keine vergleichbaren Daten erhoben werden. Zur Evaluierung des Stellenwertes der RTR nach HDCT analysierten wir unser eigenes Patientenkollektiv und fanden, dass vergleichbar zur Primärtherapie alle Patienten nach Salvage-HDCT, die eine partielle markernegative oder markerpositive Remission erreicht haben, einer RTR zugeführt werden sollten. Bis auf intrazerebrale Reste sollten alle residuellen Tumormanifestationen komplett reseziert werden. Neben der Optimierung der therapeutischen Möglichkeiten ist auch die Minimierung der chemotherapieassoziierten Toxizitäten ein wesentlicher Bestandteil meiner wissenschaftlichen Arbeit. Aus diesem Grund evaluierten wir die Wirksamkeit der Substanz Amifostin im Hinblick auf die Verringerung von Toxizitäten, die Wirkung auf die Mobilisierung von peripheren Blutstammzellen und den Einfluß auf die Rekonstitution des Immunstatus bei Patienten mit rezidivierten oder progredienten Keimzelltumoren, die mittels einer konventionellen Chemotherapie und anschließender HDCT behandelt wurden. Der Einsatz von Amifostin erbrachte in diesem Zusammenhang und in diesem Patientenkollektiv keinen therapeutischen oder prophylaktischen Nutzen, so dass dessen Verwendung bei Patienten mit Keimzelltumoren nicht generell empfohlen werden kann.
Overall, patients with relapsed or progressive germ cell tumors (GCT) after cisplatin-based chemotherapy have a low chance of cure. Using conventional-dose chemotherapy as salvage treatment only 15-30% of the patients will become long-term survivors. It is well known that the majority of these patients will ultimately die of their disease. Therefore, improvment of standard treatment is clearly desirable. Our data has been established high-dose chemotherapy (HDCT) as an effective salvage modality with an event-free survival of 30-60%. A matched-pair analysis showed an advantage for HDCT compared with conventional-dose chemotherapy with improvement in event-free and overall survival of more than 10%. Furthermore, due to increasing clinical experience in the management of side-effects, the use of peripheral blood progenitor cells, and the availability of hematopoietic growth factors, HDCT has become relatively safe. In GCT patients with relapsed or rogressive disease HDCT has been demonstrated as a feasible and safe treatment concept which will be curative for a substantial proportion of these patients. Therefore, HDCT should be administered in patients with first relapse and unfavorable prognostic factors and as second or subsequent salvage treatment. Surgical resection of residual tumors (RTR) after first-line chemotherapy is recommended in patients with metastatic GCT. Necrosis will be the only histological finding in the majority of these patients. However, in others mature teratoma, viable cancer consisting of residual GCT, non germ-cell tumors, undifferentiated cancer or a combination of these histologies may be found. Whereas the resection of necrosis offers no therapeutic benefit, resection of mature teratoma or viable cancer adds to long-term event-free and overall survival in these patients. However, limited data exist on the results of surgery and the respective histologies in patients after first or subsequent salvage treatment with HDCT. To assess the contribution of RTR in this setting, we retrospectively analyzed a cohort of patients who had been treated with HDCT for relapsed or refractory GCT. Our data show that RTR contributes to the overall treatment outcome and should be offered to all patients with a partial remission after HDCT. Complete resections of all residual tumors outside the CNS should be attempted. Furthermore, we assessed the efficacy of amifostine for protection from chemotherapy-induced toxicities, for peripheral blood progenitor cell mobilization and for immune-reconstitution in patients treated with conventional-dose paclitaxel, ifosfamide, cisplatin (TIP) and high-dose carboplatin, etoposide and thiotepa (CET) followed by PBPC rescue. In conclusion, amifostine additional to conventional-dose chemotherapy or HDCT showed no unequivocal advantage in protection from treatment-related toxicities and had no effect neither on PBPC mobilization nor on immune-reconstitution.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Tumor Residual"

1

Ignatiadis, Michail, Christos Sotiriou, and Klaus Pantel, eds. Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-28160-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

International Symposium on the Effects of Therapy on the Biology and Kinetics of the Surviving Tumor (1989 Vancouver, B.C.). Effects of therapy on biology and kinetics of the residual tumor: Proceedings of an International Symposium on the Effects of Therapy on the Biology and Kinetics of the Surviving Tumor, held in Vancouver, British Columbia, Canada, February 15-18, 1989. Edited by Ragaz J. 1945-. New York: Wiley-Liss, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mario, Dicato, Mathé Georges, and Reizenstein Peter 1928-, eds. Management of minimal residual malignancy in man. Oxford: Pergamon, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

F, Zipf Theodore, and Johnston Dennis A, eds. Leukemia and lymphoma: Detection of minimal residual disease. Totowa, N.J: Humana Press, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pantel, Klaus, Michail Ignatiadis, and Christos Sotiriou. Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Pantel, Klaus, Michail Ignatiadis, and Christos Sotiriou. Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer. Springer London, Limited, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Pantel, Klaus, Michail Ignatiadis, and Christos Sotiriou. Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer. Springer Berlin / Heidelberg, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Minimal Residual Disease And Circulating Tumor Cells In Breast Cancer. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Reizenstein, P., and G. Mathe. Managing Minimal Residual Malignancy in Man (Medical Oncology and Tumor Pharmacotherapy). Elsevier Science Publishing Company, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Majmundar, Neil, and James K. Liu. Ventricular Tumors. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190696696.003.0009.

Full text
Abstract:
Central neurocytomas are rare benign tumors that are typically located in the lateral ventricles. Because they are typically intraventricular, these tumors tend to present clinically with hydrocephalus. Currently, surgical removal with a gross-total resection is the treatment of choice. Various radiotherapy techniques, including both conventional radiotherapy and stereotactic radiosurgery, have been shown to be useful in cases of residual tumor after subtotal resection and tumor recurrence. This chapter presents a clinical case of central neurocytoma that demonstrates the typical clinical and radiological findings, as well as the diagnostic workup and surgical management of these tumors.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Tumor Residual"

1

Cirillo, Luigi, Antonella Bacci, Raffaele Agati, and Marco Leonardi. "Early Residual Tumor." In Imaging Gliomas After Treatment, 67–68. Milano: Springer Milan, 2012. http://dx.doi.org/10.1007/978-88-470-2370-3_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Caranci, Ferdinando, Francesco Briganti, and Arturo Brunetti. "Late Residual Tumor." In Imaging Gliomas After Treatment, 69–72. Milano: Springer Milan, 2012. http://dx.doi.org/10.1007/978-88-470-2370-3_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Stecco, Alessandro, Francesco Fabbiano, Sara Zizzari, Gerardo Di Nardo, Mariangela Lombardi, Andrea Pietro Sponghini, and Alessandro Carriero. "Low-grade Residual Tumor." In Imaging Gliomas After Treatment, 73–77. Milano: Springer Milan, 2012. http://dx.doi.org/10.1007/978-88-470-2370-3_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Fabbiano, Francesco, Alessandro Stecco, Sara Zizzari, Gerardo Di Nardo, Anthony Azubuike Obaze, Mariangela Lombardi, and Alessandro Carriero. "High-grade Residual Tumor." In Imaging Gliomas After Treatment, 89–92. Milano: Springer Milan, 2012. http://dx.doi.org/10.1007/978-88-470-2370-3_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Stecco, Alessandro, Sara Zizzari, Francesco Fabbiano, Gerardo Di Nardo, Mariangela Lombardi, Ignazio Divenuto, and Alessandro Carriero. "High-grade Residual Tumor." In Imaging Gliomas After Treatment, 93–94. Milano: Springer Milan, 2012. http://dx.doi.org/10.1007/978-88-470-2370-3_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Teicher, Beverly A. "Models for Minimal Residual Tumor." In Anticancer Drug Development Guide, 183–96. Totowa, NJ: Humana Press, 1997. http://dx.doi.org/10.1007/978-1-4615-8152-9_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Stecco, Alessandro, Sara Zizzari, Francesco Fabbiano, Gerardo Di Nardo, Mariangela Lombardi, Emanuele Malatesta, and Alessandro Carriero. "Medium-low-grade Residual Tumor." In Imaging Gliomas After Treatment, 79–80. Milano: Springer Milan, 2012. http://dx.doi.org/10.1007/978-88-470-2370-3_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Stecco, Alessandro, Sara Zizzari, Francesco Fabbiano, Gerardo Di Nardo, Mariangela Lombardi, Giuseppe Fiscer, and Alessandro Carriero. "Medium-low-grade Residual Tumor." In Imaging Gliomas After Treatment, 81–84. Milano: Springer Milan, 2012. http://dx.doi.org/10.1007/978-88-470-2370-3_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Stecco, Alessandro, Francesco Fabbiano, Sara Zizzari, Gerardo Di Nardo, Mariangela Lombardi, Lorenzo Fortunelli, and Alessandro Carriero. "Medium-low-grade Residual Tumor." In Imaging Gliomas After Treatment, 85–88. Milano: Springer Milan, 2012. http://dx.doi.org/10.1007/978-88-470-2370-3_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pantel, K., and M. Otte. "Disseminated Tumor Cells: Diagnosis, Prognostic Relevance, and Phenotyping." In Minimal Residual Disease in Melanoma, 14–24. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-59537-0_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Tumor Residual"

1

Stylianopoulos, Triantafyllos, John D. Martin, Vikash P. Chauhan, Lance L. Munn, and Rakesh K. Jain. "Residual Stresses in Solid Tumors: Implications to Tumor Growth and Drug Delivery." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80235.

Full text
Abstract:
The uncontrolled growth of cancer cells within a confined tissue space generates residual stresses in solid tumors [1,2]. These stresses contribute to tumor progression, pathological cellular behavior, and compression of lymphatic and blood vessels [3–5]. A major consequence of vascular compression is a decrease in pathways available for blood flow and delivery of diagnostic and therapeutic agents, resulting in insufficient and heterogeneous delivery of chemotherapy and nanomedicine. The reduced perfusion also causes hypoxia and acidity — two important barriers to treatment efficacy and promoters of malignancy. In this work, we developed a strategy to quantify growth-induced residual stresses in tumors and investigate whether stress levels affect tumor growth rate and delivery of therapeutic agents. We found that stress levels are elevated in solid tumors and are sufficient to cause the collapse of blood vessels. In addition high stress levels were correlated to slower tumor growth.
APA, Harvard, Vancouver, ISO, and other styles
2

Nguyen, Chanh D. Tr, Huu-Hung Dao, Minh-Thanh Huynh, and Tan Phu Ward. "ResCap: Residual Capsules Network for Medical Image Segmentation." In 2019 Kidney Tumor Segmentation Challenge: KiTS19. University of Minnesota Libraries Publishing, 2019. http://dx.doi.org/10.24926/548719.058.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wei, Nana, Yijing Zhu, Yating Nie, Shiyu Fan, Yuanchen Sun, and Xiaoqi Zheng. "Purification of tumor methylomes through residual decomposition." In 2022 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). IEEE, 2022. http://dx.doi.org/10.1109/bibm55620.2022.9995363.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Cruz, Valéria Fernandes Roppa, Marcelo Ribeiro da Luz Cruz, Alfredo de Almeida Cunha, Marcelle Gomes Pinheiro Maia Lessa, and Renato de Souza Bravo. "BREAST ULTRASONOGRAPHY IN THE MEASUREMENT OF RESIDUAL TUMOR AFTER NEOADJUVANT CHEMOTHERAPY." In XXIV Congresso Brasileiro de Mastologia. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s1014.

Full text
Abstract:
Introduction: The role of primary chemotherapy in breast cancer is well established and has positively impacted the number of conservative surgeries. However, for effective locoregional control, it is necessary for complete resection of the residual tumor, with histopathological free margins. Preoperative evaluation of the residual tumor is essential. A clinical examination is impaired due to tissue alterations induced by chemotherapy, and the use of imaging methods had conflicting results. Objective: The aim of this study was to evaluate the agreement between the ultrasound measurement and the histopathological measurement of the residual tumor in breast cancer patients undergoing neoadjuvant chemotherapy. Methods: A cross-sectional study was conducted comparing the average and other measures of dispersion of the echographic and histopathological measurements of the residual tumor. Additionally, we compared the average and other measures of dispersion of the individual differences between the echographic and histopathological measurements of the residual tumor. The scenario was a quaternary hospital in Rio de Janeiro where breast cancer patients were treated. Results: The average ultrasound measurement was 18 mm (95%CI 13.75–22.25), with a median of 16. The average histopathological measurement was 16 mm (95%CI 11.62–20.38), with a median of 12. The average of the individual differences between the echographic and histopathological measurements of the residual tumor was 2 mm (95%CI 0.38–4.38), with a median of 2 mm. Conclusion: Ultrasonography is an effective tool in the preoperative evaluation of breast cancer patients undergoing primary chemotherapy.
APA, Harvard, Vancouver, ISO, and other styles
5

Qi, Lin, Shuangwei Liu, and Ying Wei. "2.5D U-Net with Dense/Residual Layers and Global Context Blocks for Kidney Tumor Segmentation." In 2019 Kidney Tumor Segmentation Challenge: KiTS19. University of Minnesota Libraries Publishing, 2019. http://dx.doi.org/10.24926/548719.066.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Narayan, Suresh B., Atam P. Dhawan, Jamal M. Taha, Mary Gaskill-Shipley, Michael Lamba, Alok Sarwal, and Yateen S. Chitre. "Early detection of postoperative residual tumor using image subtraction." In Medical Imaging 1995, edited by Murray H. Loew. SPIE, 1995. http://dx.doi.org/10.1117/12.208753.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ishikawa, Yota, Kiyotada Washiya, Kota Aoki, and Hiroshi Nagahashi. "Brain tumor classification of microscopy images using deep residual learning." In SPIE BioPhotonics Australasia, edited by Mark R. Hutchinson and Ewa M. Goldys. SPIE, 2016. http://dx.doi.org/10.1117/12.2242711.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kartheeban, K., Kapula Kalyani, Sai Krishna Bommavaram, Divya Rohatgi, Mathur Nadarajan Kathiravan, and S. Saravanan. "Intelligent Deep Residual Network based Brain Tumor Detection and Classification." In 2022 International Conference on Automation, Computing and Renewable Systems (ICACRS). IEEE, 2022. http://dx.doi.org/10.1109/icacrs55517.2022.10029146.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Reza Obeidavi, Mohammad, and Keivan Maghooli. "Tumor Detection in Brain MRI using Residual Convolutional Neural Networks." In 2022 12th Iranian/Second International Conference on Machine Vision and Image Processing (MVIP). IEEE, 2022. http://dx.doi.org/10.1109/mvip53647.2022.9738767.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Zhao, Haixia. "Recognition and Segmentation of Gastric Tumor Based on Deep Residual Network." In 2020 IEEE 3rd International Conference on Information Systems and Computer Aided Education (ICISCAE). IEEE, 2020. http://dx.doi.org/10.1109/iciscae51034.2020.9236854.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Tumor Residual"

1

Kengsakul, Malika, Gatske Nieuwenhuyzen – de Boer, and Heleen van Beekhuizen. Radiological factors associated with residual disease after cytoreductive surgery for advanced ovarian cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2023. http://dx.doi.org/10.37766/inplasy2023.1.0059.

Full text
Abstract:
Review question / Objective: Which radiological factors associated with incomplete cytoreduction (gross residual disease) after cytoreductive surgery (CRS) for advanced ovarian cancer? Condition being studied: Findings of CT scan and discussion in the multidisciplinary tumor board meeting (MDO) are crucial to determine the therapeutic strategy for individual ovarian cancer patients. Preferably, patients undergo primary cytoreductive surgery (CRS) followed by adjuvant chemotherapy. However, when complete cytoreduction is not considered feasible, neoadjuvant chemotherapy followed by interval cytoreductive surgery and adjuvant chemotherapy is indicated. In patients with advanced stage epithelial ovarian cancer (EOC), maximal cytoreduction to no gross residual tumor (complete cytoreduction) is known to associated with the best overall survival.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Tumor Residual' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography